Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
Medulloblastoma (MB), a primary tumor of the central nervous system, is among the most prevalent pediatric neoplasms. The median age of diagnosis is six. Conventional therapies include surgical resection of the tumor with subsequent radiation and chemotherapy. However, these therapies often cause se...
Guardado en:
Autores principales: | Marije J. Voskamp, Shuang Li, Kim R. van Daalen, Sandra Crnko, Toine ten Broeke, Niels Bovenschen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f9ba5ad4231f4e77a01d0a50ea3e9f7d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
por: Xin Cai, et al.
Publicado: (2021) -
The impact of magnetic resonance imaging spectroscopy parameters on differentiating between paediatric medulloblastoma and ependymoma
por: Nguyen Minh Duc
Publicado: (2021) -
Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment
por: Jagmohan Singh, et al.
Publicado: (2021) -
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Anwen Xiong, et al.
Publicado: (2021) -
Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
por: Shijie Shang, et al.
Publicado: (2021)